# Eylea 2mg Treat-and-Treat Protocol
# V2-compliant fixed interval dosing protocol
# 
# Note: Clinical parameters require calibration to match trial data
# Disease transitions and vision outcomes to be determined by simulation

# Required metadata
name: "Eylea 2mg Treat-and-Treat V2"
version: "2.0.0"
created_date: "2025-01-06"
author: "Clinical Economics Integration Team"
description: "Fixed-interval aflibercept 2mg protocol with defined dosing schedule"

# Required protocol parameters (all in days for V2)
protocol_type: "fixed_interval"
min_interval_days: 56      # 8 weeks (maintenance phase)
max_interval_days: 63      # 9 weeks (allowing 7-day window)
extension_days: 0          # No extensions in fixed protocol
shortening_days: 0         # No shortenings in fixed protocol

# Required disease transitions - TO BE CALIBRATED
# Placeholder values - need calibration to trial data
disease_transitions:
  NAIVE:
    NAIVE: 0.00
    STABLE: 0.25
    ACTIVE: 0.25
    HIGHLY_ACTIVE: 0.50   # Placeholder - needs calibration
    
  STABLE:
    NAIVE: 0.00
    STABLE: 0.25
    ACTIVE: 0.25
    HIGHLY_ACTIVE: 0.50   # Placeholder - needs calibration
    
  ACTIVE:
    NAIVE: 0.00
    STABLE: 0.25
    ACTIVE: 0.25
    HIGHLY_ACTIVE: 0.50   # Placeholder - needs calibration
    
  HIGHLY_ACTIVE:
    NAIVE: 0.00
    STABLE: 0.25
    ACTIVE: 0.25
    HIGHLY_ACTIVE: 0.50   # Placeholder - needs calibration

# Required vision change model - TO BE CALIBRATED
# Placeholder values - need calibration to trial data
vision_change_model:
  naive_treated:
    mean: 0.0         # Placeholder - needs calibration
    std: 1.0          # Placeholder - needs calibration
    
  naive_untreated:
    mean: -1.5        # Natural history (may have evidence)
    std: 2.0
    
  stable_treated:
    mean: 0.0         # Placeholder - needs calibration
    std: 1.0          # Placeholder - needs calibration
    
  stable_untreated:
    mean: -0.5
    std: 1.0
    
  active_treated:
    mean: 0.0         # Placeholder - needs calibration
    std: 1.0          # Placeholder - needs calibration
    
  active_untreated:
    mean: -2.0
    std: 2.5
    
  highly_active_treated:
    mean: 0.0         # Placeholder - needs calibration
    std: 1.0          # Placeholder - needs calibration
    
  highly_active_untreated:
    mean: -4.0
    std: 3.5

# Required treatment effect on transitions - TO BE CALIBRATED
treatment_effect_on_transitions:
  NAIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.0      # Placeholder - needs calibration
      ACTIVE: 1.0      # Placeholder - needs calibration
      HIGHLY_ACTIVE: 1.0  # Placeholder - needs calibration
      
  STABLE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.0      # Placeholder - needs calibration
      ACTIVE: 1.0      # Placeholder - needs calibration
      HIGHLY_ACTIVE: 1.0  # Placeholder - needs calibration
      
  ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.0      # Placeholder - needs calibration
      ACTIVE: 1.0      # Placeholder - needs calibration
      HIGHLY_ACTIVE: 1.0  # Placeholder - needs calibration
      
  HIGHLY_ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.0      # Placeholder - needs calibration
      ACTIVE: 1.0      # Placeholder - needs calibration
      HIGHLY_ACTIVE: 1.0  # Placeholder - needs calibration

# Required baseline vision parameters
baseline_vision:
  mean: 55           # ETDRS letters - typical trial entry
  std: 15
  min: 25
  max: 85

# Required discontinuation rules
discontinuation_rules:
  # Annual review discontinuation
  stable_at_annual_review:
    criteria:
      months_on_treatment: 12
      vision_stable: true
      patient_choice: true
    probability: 0.10    # To be validated
    reason: "stable_disease"
    
  # Non-compliance
  non_compliance:
    criteria:
      missed_consecutive_visits: 2
      months_since_last_visit: 4
    probability: 0.95
    reason: "lost_to_follow_up"
    
  # Treatment failure (assessed at annual review)
  treatment_failure:
    criteria:
      vision_loss_from_baseline: 30
      assessed_at: "annual_review"
    probability: 0.80
    reason: "inadequate_response"
    
  # Safety
  adverse_event:
    criteria:
      severe_adverse_event: true
    probability: 0.90
    reason: "adverse_event"

# Protocol-specific parameters
treat_and_treat_parameters:
  # Loading phase specifics
  loading_phase:
    number_of_doses: 3
    dose_1_to_2_days: [28, 35]    # 4-5 week window
    dose_2_to_3_days: [28, 35]    # 4-5 week window
    
  # Maintenance phase
  maintenance_phase:
    interval_days: [56, 63]        # 8-9 week window
    starts_after_dose: 3
    
  # Monitoring visits
  monitoring_schedule:
    clinical_assessment:
      timing: "between_dose_3_and_4"
      window_days: 14
      components: ["oct", "iop", "va", "clinical_exam"]
      
    annual_review:
      timing: "yearly"
      window_days: 14              # Within 2 weeks
      components: ["oct", "iop", "va", "clinical_exam", "treatment_review"]

# Economic integration
economic_parameters:
  # Visit types specific to treat-and-treat
  visit_types:
    injection_only:
      components: ["drug_administration", "brief_check"]
      staff_time_minutes: 30
      
    clinical_assessment:
      components: ["oct_scan", "iop_check", "visual_acuity", "clinical_exam"]
      staff_time_minutes: 45
      
    annual_review:
      components: ["oct_scan", "iop_check", "visual_acuity", "clinical_exam", "consultation"]
      staff_time_minutes: 60
      
  # Fixed dosing schedule
  annual_visits:
    year_1:
      injections: 6.5              # 3 loading + 3.5 maintenance (calculated)
      monitoring: 2                # Clinical assessment + annual
      total: 8.5
    year_2_plus:
      injections: 6                # Fixed q8-9 weeks (calculated)
      monitoring: 1                # Annual review only
      total: 7

# Clinical evidence basis - TO BE ADDED
clinical_evidence:
  # Reference trials to be identified
  # Expected outcomes to be determined by simulation
  # No assumptions about effectiveness made